ABBV
Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 149.83$. Average daily volumn in 3 months 7.32M. Market cap 271.78B
Stock symbol : ABBV. Exchange : NYSE. Currency : USD Lastest price : 153.80$. Total volume : 3.65M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
AbbVie Inc. (ABBV)
Last Price
153.80$Change
0.64Volume
3.65M
Previous Close | 153.16 |
Open | 153.08 |
Day Range | 151.46-153.85 |
Bid | 151.00 x 1.3k |
Ask | 153.59 x 900 |
Volume | 3.65M |
Average Volume | 7.32M |
Market Cap | 271.78B |
Beta | 0.81 |
52 Week Range | 105.56-175.91 |
Trailing P/E | 22.07 |
Foward P/E | 12.86 |
Dividend (Yield %) | 3.67% |
Ex-Dividend Date | 2022-07-14 |
Financial Details

Organization
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Market Cap:
271.78BRevenue:
56.2BTotal Assets:
146.53BTotal Cash:
9.75B
News about "AbbVie Inc."
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Great Valley Advisor Group Inc.
Source from : Defense World - 10 hours ago
Great Valley Advisor Group Inc. increased its stake in AbbVie Inc. (NYSE:ABBV – Get Rating) by 3.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange ...See details»
AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Brokerages
Source from : Defense World - 13 hours ago
AbbVie Inc. (NYSE:ABBV – Get Rating) has received a consensus rating of “Moderate Buy” from the nineteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has ...See details»
AbbVie Inc. (ABBV) Outlook: Revisiting The Past For Future Insights
Source from : stocksregister - 2 days ago
AbbVie Inc. (NYSE:ABBV) at last check was buoying at $152.49 on Thursday, June 30, with a fall of -1.07% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»
Is AbbVie About To Get A New Blockbuster Drug?
Source from : Nasdaq - 5 days ago
L ast month, AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the compound ABBV-951 to treat motor fluctuations in patients with advanced ...See details»
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Source from : Nasdaq - 5 days ago
ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor ...See details»
Spire Wealth Management Reduces Position in AbbVie Inc. (NYSE:ABBV)
Source from : ETF Daily News - 4 days ago
Spire Wealth Management decreased its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 20.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 60,790 ...See details»
Ritholtz Wealth Management Grows Stake in AbbVie Inc. (NYSE:ABBV)
Source from : ETF Daily News - 5 days ago
Ritholtz Wealth Management increased its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 279.3% in the first quarter, according to the company in its most recent filing with the Securities & ...See details»
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
Source from : Yahoo News Singapore - 3 days ago
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.See details»
AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding
Source from : YAHOO!Finance - 5 days ago
Headquartered in Illinois, AbbVie (NYSE:ABBV) is a well-respected pharmaceutical businesses with a broad range of medical treatments and solutions. If you’re going to pick a pharmaceutical-market ...See details»
AbbVie Declares Quarterly Dividend
Source from : YAHOO!Finance - 9 days ago
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.See details»
AbbVie Rallies After Its Test of the Rising 200-Day Moving Average Line
Source from : TheStreet.com - 5 days ago
In this daily bar chart of , below, we can see that prices rallied back above the 50-day moving average line after touching/testing the rising 200-day line earlier this month. The ...See details»
Why AbbVie Stock Is Trading Higher Today
Source from : Benzinga.com - 11 days ago
AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support ...See details»
Abbvie Inc ABBV Trading Report
Source from : MarketWatch - 19 days ago
This report optimizes trading in Abbvie Inc (NASDAQ: ABBV) with integrated risk controls. Use the basic rules of Technical Analysis. Here are some examples: if ABBV is testing support the signal ...See details»
Baron Funds: “We Retain Conviction in AbbVie (ABBV)”
Source from : Insider Monkey - 18 days ago
In its Q1 2022 investor letter, Baron Health Care Fund mentioned AbbVie Inc. (NYSE:ABBV) and explained its insights for the company. Founded in 2013, AbbVie Inc. (NYSE:ABBV) is a North Chicago ...See details»